Abstract
When using polyspecific antihuman globulin (AHG) reagents to detect unexpected antibodies or for crossmatching, reactivity in the AHG phase may be due exclusively to the AHG anticomplement component. A lengthy evaluation may be needed to prove that the reactivity is caused by a "nuisance" antibody, one that is clinically insignificant. Clinically significant transfusion intolerance is rare when caused by blood group alloantibodies, which are detected only with AHG sera that contain anticomplement activity. Using monospecific anti-IgG AHG reagents to detect unexpected antibodies offers reliability while avoiding interference from some common and clinically insignificant IgM complement-fixing antibodies, and thereby saves time and expense.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
